GAMMA Investing LLC Boosts Stake in Privia Health Group, Inc. (NASDAQ:PRVA)

GAMMA Investing LLC raised its stake in Privia Health Group, Inc. (NASDAQ:PRVA - Free Report) by 4,683.8% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 64,342 shares of the company's stock after purchasing an additional 62,997 shares during the period. GAMMA Investing LLC owned about 0.05% of Privia Health Group worth $1,444,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds also recently bought and sold shares of the company. First Horizon Advisors Inc. raised its position in Privia Health Group by 53.8% in the 4th quarter. First Horizon Advisors Inc. now owns 1,807 shares of the company's stock valued at $35,000 after purchasing an additional 632 shares in the last quarter. EverSource Wealth Advisors LLC raised its position in shares of Privia Health Group by 7,833.3% during the 4th quarter. EverSource Wealth Advisors LLC now owns 2,380 shares of the company's stock worth $47,000 after acquiring an additional 2,350 shares in the last quarter. Quadrant Capital Group LLC raised its position in shares of Privia Health Group by 11.8% during the 4th quarter. Quadrant Capital Group LLC now owns 4,855 shares of the company's stock worth $95,000 after acquiring an additional 511 shares in the last quarter. Neo Ivy Capital Management raised its position in shares of Privia Health Group by 81.5% during the 4th quarter. Neo Ivy Capital Management now owns 6,540 shares of the company's stock worth $127,000 after acquiring an additional 2,936 shares in the last quarter. Finally, PNC Financial Services Group Inc. raised its position in shares of Privia Health Group by 8.0% during the 4th quarter. PNC Financial Services Group Inc. now owns 7,169 shares of the company's stock worth $140,000 after acquiring an additional 533 shares in the last quarter. Institutional investors and hedge funds own 94.48% of the company's stock.

Insider Buying and Selling at Privia Health Group

In other Privia Health Group news, CFO David Mountcastle sold 5,630 shares of Privia Health Group stock in a transaction that occurred on Wednesday, April 2nd. The stock was sold at an average price of $22.38, for a total value of $125,999.40. Following the transaction, the chief financial officer now directly owns 179,676 shares in the company, valued at approximately $4,021,148.88. This trade represents a 3.04% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Matthew Shawn Morris sold 10,309 shares of Privia Health Group stock in a transaction that occurred on Wednesday, April 30th. The shares were sold at an average price of $23.33, for a total value of $240,508.97. Following the completion of the transaction, the director now owns 59,792 shares in the company, valued at $1,394,947.36. This trade represents a 14.71% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 51,579 shares of company stock worth $1,226,367. 10.70% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on PRVA shares. JMP Securities reissued a "market outperform" rating and set a $29.00 target price on shares of Privia Health Group in a research report on Monday, April 28th. Piper Sandler raised their target price on Privia Health Group from $25.00 to $40.00 and gave the stock an "overweight" rating in a research report on Friday, February 28th. Truist Financial raised their target price on Privia Health Group from $27.00 to $28.00 and gave the stock a "buy" rating in a research report on Thursday, April 10th. Canaccord Genuity Group raised their target price on Privia Health Group from $29.00 to $30.00 and gave the stock a "buy" rating in a research report on Friday, February 28th. Finally, Needham & Company LLC reaffirmed a "buy" rating and set a $30.00 price target on shares of Privia Health Group in a research report on Thursday, April 10th. One equities research analyst has rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of "Buy" and an average price target of $27.77.

Privia Health Group Stock Down 2.6%

PRVA traded down $0.58 during trading on Wednesday, hitting $21.81. 909,223 shares of the stock were exchanged, compared to its average volume of 744,289. The stock has a fifty day moving average price of $23.45 and a two-hundred day moving average price of $22.84. Privia Health Group, Inc. has a 1-year low of $16.37 and a 1-year high of $26.09. The firm has a market capitalization of $2.66 billion, a P/E ratio of 181.77, a PEG ratio of 3.58 and a beta of 0.83.

Privia Health Group Company Profile

Privia Health Group, Inc operates as a national physician-enablement company in the United States. The company collaborates with medical groups, health plans, and health systems to optimize physician practices, enhance patient experiences, and reward doctors for delivering care in-person and virtual settings.